ストックスクリーナーアプリを入手
75.45
2.47%
1.62
前日終値:
$73.83
開ける：
$73.71
24時間の取引高:
1.10M
Relative Volume:
0.25
時価総額：
$44.46B
収益：
$5.54B
当期純損益:
$4.18B
株価収益率:
10.78
EPS:
7
ネットキャッシュフロー:
$623.10M
1週間 パフォーマンス:
+1.12%
1か月 パフォーマンス:
+0.89%
6か月 パフォーマンス:
+1.13%
1年 パフォーマンス:
-16.77%
1日の値動き範囲:
$73.38
$75.69
1週間の範囲:
$72.42
$75.69
52週間の値動き範囲:
$58.93
$95.25
Edwards Lifesciences Corp Stock (EW) Company Profile
名前
Edwards Lifesciences Corp
セクター
電話
(949) 250-2500
住所
ONE EDWARDS WAY, IRVINE, CA
EW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
75.45 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
|
ABT
Abbott Laboratories
|
132.72 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
101.53 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
374.94 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.10 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-24 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | アップグレード | Stifel | Hold → Buy |
| 2025-01-16 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-09-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-31 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-07-25 | ダウングレード | Truist | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2024-05-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-03-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-02-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-28 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-03-29 | 開始されました | UBS | Neutral |
| 2023-03-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | ダウングレード | Bernstein | Outperform → Underperform |
| 2023-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | ダウングレード | Stifel | Buy → Hold |
| 2022-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 開始されました | Mizuho | Buy |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 開始されました | Truist | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-03-16 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-27 | 繰り返されました | Citigroup | Buy |
| 2022-01-27 | 繰り返されました | Evercore ISI | Outperform |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Buy |
| 2022-01-27 | 繰り返されました | UBS | Neutral |
| 2021-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-12-15 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-12-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-30 | 繰り返されました | Deutsche Bank | Hold |
| 2021-07-30 | 繰り返されました | Jefferies | Buy |
| 2021-07-30 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-07-30 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-30 | 繰り返されました | Stifel | Buy |
| 2021-07-30 | 繰り返されました | UBS | Neutral |
| 2021-07-30 | 繰り返されました | Wells Fargo | Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-04-05 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-11 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Underperform |
| 2020-04-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Outperform |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-09-23 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-24 | 繰り返されました | BofA/Merrill | Buy |
| 2019-03-18 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-01-18 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 開始されました | Deutsche Bank | Hold |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-16 | 開始されました | Barclays | Underweight |
| 2018-10-02 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | ダウングレード | Guggenheim | Buy → Neutral |
すべてを表示
Edwards Lifesciences Corp (EW) 最新ニュース
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - MSN
Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments - Law360
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Is Edwards Lifesciences Stock Underperforming the Dow? - MSN
Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - MarketScreener
Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com
Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com
Edwards Lifesciences stock rises following competitor’s exit - Investing.com
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at StockNews.com - Defense World
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post
Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes - Cardiovascular Business
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com
Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com
FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal
Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
Edwards Lifesciences Corp (EW) 財務データ
収益
当期純利益
現金流量
EPS
Edwards Lifesciences Corp (EW) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Wood Larry L | Global President TAVR & Surg |
Jun 16 '25 |
Sale |
75.23 |
8,950 |
673,268 |
206,900 |
0.94%
0.11%
大文字化:
|
ボリューム (24 時間):